These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1854678)

  • 1. Prostaglandin E1 suppression of platelet aggregation response in schizophrenia.
    Kaiya H
    Schizophr Res; 1991; 5(1):67-80. PubMed ID: 1854678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet prostaglandin E1 hyposensitivity in schizophrenia: decrease in cyclic AMP formation and in inhibitory effects on aggregation.
    Kaiya H; Ofuji M; Nozaki M; Tsurumi K
    Psychopharmacol Bull; 1990; 26(3):381-4. PubMed ID: 2177206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin receptor sensitivity in psychiatric disorders.
    Kanof PD; Johns C; Davidson M; Siever LJ; Coccaro EF; Davis KL
    Arch Gen Psychiatry; 1986 Oct; 43(10):987-93. PubMed ID: 3019269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet aggregation response in schizophrenia and prostaglandin E1.
    Kaiya H; Imai H; Muramatsu Y; Nozaki M; Fujimura H; Adachi S; Namba M
    Psychiatry Res; 1983 Aug; 9(4):309-18. PubMed ID: 6139836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V; Armstrong PC; Warner TD; Curzen N
    Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
    Kikura M; Kazama T; Ikeda T; Sato S
    Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation.
    Katzenschlager R; Weiss K; Rogatti W; Peskar BA; Sinzinger H
    Prostaglandins Leukot Essent Fatty Acids; 1992 Mar; 45(3):207-10. PubMed ID: 1589447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ADP-induced platelet aggregation by reduced factor Xa.
    Sinha AK; Colman RW
    Eur J Biochem; 1983 Oct; 136(1):57-62. PubMed ID: 6617661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of adenosine diphosphate-induced intravascular aggregation of rat platelets in vivo by 6-oxo-prostaglandin E1.
    Oyekan AO; Botting JH
    Prostaglandins; 1987 Sep; 34(3):359-66. PubMed ID: 3324168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.
    Fitscha P; Kaliman J; Sinzinger H
    Am J Hematol; 1985 May; 19(1):13-9. PubMed ID: 3885723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of prostaglandins E1 and E2 on thrombocyte form and aggregation].
    Antonikov IM; Alekseev OV; Chernukh AM
    Biull Eksp Biol Med; 1982 Apr; 93(4):11-3. PubMed ID: 6952942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro.
    Wilsoncroft PS; Lofts FJ; Griffiths RJ; Moore PK
    J Pharm Pharmacol; 1985 Feb; 37(2):139-41. PubMed ID: 2858551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-keto-prostaglandin E1 is not equipotent to prostacyclin (PGI2) as an antiaggregatory agent.
    Miller OV; Aiken JW; Shebuski RJ; Gorman RR
    Prostaglandins; 1980 Aug; 20(2):391-400. PubMed ID: 6251513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased inhibition of platelet aggregation by PGE1 in children with cystic fibrosis and their parents.
    Samuels CE; Robinson PG; Elliott RB
    Prostaglandins; 1975 Oct; 10(4):617-21. PubMed ID: 1105695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibition by adenosine or by prostaglandin E1 of human platelet aggregation induced by adenosine 5'-O-(1-thiodiphosphate) and adenosine 5'-O-(2-thiodiphosphate).
    Cusack NJ; Hourani SM
    Br J Pharmacol; 1982 Feb; 75(2):257-9. PubMed ID: 6892270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of platelet aggregation by the filtration pressure method (author's transl)].
    Matsubara I
    Nihon Yakurigaku Zasshi; 1981 Sep; 78(3):173-84. PubMed ID: 7035311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of Soviet-made prostaglandin E1 on the aggregation of thrombocytes and erythrocytes].
    Lakin KM; Makarov VA; Ovnatanova MS; Azhgikhin IS
    Farmakol Toksikol; 1976; 39(4):436-40. PubMed ID: 1027569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Keto-prostaglandin E1 inhibits the aggregation of human platelets.
    Wong PY; McGiff JC; Sun FF; Lee WH
    Eur J Pharmacol; 1979 Dec; 60(2-3):245-8. PubMed ID: 393526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects on platelet aggregation of oral prostaglandin E2 used for the induction of labour.
    Myatt L; Elder MG
    Br J Obstet Gynaecol; 1975 Jun; 82(6):449-52. PubMed ID: 1138835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between the inhibition of aggregation and the concentration of cAMP in human and rat platelets.
    Michel H; Caen JP; Born GV; Miller R; D'Auriac GA; Meyer P
    Br J Haematol; 1976 May; 33(1):27-38. PubMed ID: 178342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.